Solventum Co. (NYSE:SOLV) Shares Sold by TrinityPoint Wealth LLC

TrinityPoint Wealth LLC lessened its holdings in shares of Solventum Co. (NYSE:SOLV) by 38.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,497 shares of the company’s stock after selling 13,148 shares during the period. TrinityPoint Wealth LLC’s holdings in Solventum were worth $1,499,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Tokio Marine Asset Management Co. Ltd. grew its position in Solventum by 4.2% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock valued at $346,000 after buying an additional 200 shares in the last quarter. National Bank of Canada FI increased its stake in shares of Solventum by 4.0% during the second quarter. National Bank of Canada FI now owns 6,093 shares of the company’s stock valued at $314,000 after acquiring an additional 236 shares during the period. IVC Wealth Advisors LLC increased its stake in shares of Solventum by 5.0% during the third quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock valued at $464,000 after acquiring an additional 318 shares during the period. Copeland Capital Management LLC bought a new stake in Solventum during the third quarter worth approximately $26,000. Finally, Mather Group LLC. acquired a new stake in Solventum in the third quarter worth approximately $27,000.

Solventum Trading Down 0.6 %

Shares of SOLV opened at $67.48 on Monday. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05. The firm’s 50 day moving average price is $70.54 and its 200 day moving average price is $62.18.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Morgan Stanley lifted their price target on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. BTIG Research started coverage on shares of Solventum in a research report on Thursday, September 5th. They issued a “neutral” rating on the stock. Wolfe Research initiated coverage on shares of Solventum in a research report on Thursday, September 26th. They set a “peer perform” rating for the company. Piper Sandler boosted their target price on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Finally, The Goldman Sachs Group increased their target price on shares of Solventum from $48.00 to $54.00 and gave the company a “sell” rating in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $68.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.